Imatinib mesylate in combination with chemotherapy in four children with de novo and advanced stage Philadelphia chromosome-positive acute lymphoblastic leukemia.
The role of imatinib in childhood Philadelphia chromosome-positive (Ph(+)) acute lymphoblastic leukemia (ALL) has not been established. We treated four children with imatinib in combination with conventional chemotherapy (CT) before stem cell transplantation (SCT). Response evaluation consisted of fluorocytometric analysis of minimal residual disease (MRD) and standard qualitative RT-PCR follow-up.
Hospital Universitario Virgen de la Arrixaca, Murcia, Spain. josel.fuster@carm.es
José Luis
JL
Fuster
Mar
M
Bermúdez
Ana
A
Galera
María Esther
ME
Llinares
Doris
D
Calle
Francisco Jose
FJ
Ortuño
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001549:Benzamides; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D009367:Neoplasm Staging; D018365:Neoplasm, Residual; D010879:Piperazines / Q000008:administration & dosage*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D011743:Pyrimidines / Q000008:administration & dosage*; D033581:Stem Cell Transplantation; D014184:Transplantation, Homologous
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate